Europe Solid Tumors Drugs Market Research Report Forecast 2017 to 2022

April 2017 | 135 pages | ID: EE4C765289EEN
S&P Consulting

Abstracts

Delivery of the Report will take 2-3 working days once order is placed.

The Europe Solid Tumors Drugs Market Research Report Forecast 2017-2022 is a valuable source of insightful data for business strategists. It provides the Solid Tumors Drugs industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Solid Tumors Drugs market study provides comprehensive data which enhances the understanding, scope and application of this report.

This report provides comprehensive analysis of

• Key market segments and sub-segments
• Evolving market trends and dynamics
• Changing supply and demand scenarios
• Quantifying market opportunities through market sizing and market forecasting
• Tracking current trends/opportunities/challenges
• Competitive insights
• Opportunity mapping in terms of technological breakthroughs

Europe Solid Tumors Drugs Market Analysis by Countries:
Germany
France
UK
Russia
Italy
Spain
Benelux

The Major players reported in the market include:
Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
AbbVie
AbGenomics
ADC Therapeutics

Europe Solid Tumors Drugs Market Analysis by Product:
Type 1
Type 2
Type 3

Europe Solid Tumors Drugs Market Analysis by Application:
Application 1
Application 2
Application 3

Reasons for Buying this Report

• This report provides pin-point analysis for changing competitive dynamics
• It provides a forward looking perspective on different factors driving or restraining market growth
• It provides a six-year forecast assessed on the basis of how the market is predicted to grow
• It helps in understanding the key product segments and their future
• It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
• It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Contents

1 SOLID TUMORS DRUGS MARKET OVERVIEW

1.1 Product Overview and Scope of Solid Tumors Drugs
1.2 Classification of Solid Tumors Drugs
  1.2.1 Type
  1.2.2 Type
  1.2.3 Type
1.3 Application of Solid Tumors Drugs
  1.3.2 Application
  1.3.3 Application
  1.3.4 Application
1.4 Solid Tumors Drugs Market States Status and Prospect (2012-2022) by Countries
  1.4.1 Germany
  1.4.2 France
  1.4.3 UK
  1.4.4 Russia
  1.4.5 Italy
  1.4.6 Spain
  1.4.7 Benelux
1.5 Europe Market Size (Value and Volume) of Solid Tumors Drugs (2012-2022)
  1.5.1 Europe Solid Tumors Drugs Sales and Growth Rate (2012-2022)
  1.5.2 Europe Solid Tumors Drugs Revenue and Growth Rate (2012-2022)

2 EUROPE ECONOMIC IMPACT ON SOLID TUMORS DRUGS INDUSTRY

2.1 Europe Macroeconomic Analysis
2.2 Europe Macroeconomic Environment Development Trend

3 SOLID TUMORS DRUGS MANUFACTURING COST ANALYSIS

3.1 Solid Tumors Drugs Key Raw Materials Analysis
  3.1.1 Key Raw Materials
  3.1.2 Price Trend of Key Raw Materials
  3.1.3 Key Suppliers of Raw Materials
  3.1.4 Market Concentration Rate of Raw Materials
3.2 Proportion of Manufacturing Cost Structure
  3.2.1 Raw Materials
  3.2.2 Labor Cost
  3.2.3 Manufacturing Process Analysis of Solid Tumors Drugs

4 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

4.1 Solid Tumors Drugs Industrial Chain Analysis
4.2 Upstream Raw Materials Sourcing
4.3 Raw Materials Sources of Solid Tumors Drugs Major Manufacturers in 2016
4.4 Downstream Buyers

5 EUROPE SOLID TUMORS DRUGS MARKET ANALYSIS BY MANUFACTURERS, TYPE AND APPLICATION

5.1 Europe Solid Tumors Drugs Market Competition by Manufacturers
  5.1.1 Europe Solid Tumors Drugs Sales and Market Share of Key Manufacturers (2015 and 2016)
  5.1.2 Europe Solid Tumors Drugs Revenue and Share by Manufacturers (2015 and 2016)
5.2 Europe Solid Tumors Drugs (Volume and Value) by Type
  5.2.1 Europe Solid Tumors Drugs Sales and Market Share by Type (2012-2017)
  5.2.2 Europe Solid Tumors Drugs Revenue and Market Share by Type (2012-2017)
5.3 Europe Solid Tumors Drugs (Volume and Value) by Countries
  5.3.1 Europe Solid Tumors Drugs Sales and Market Share by Countries (2012-2017)
  5.3.2 Europe Solid Tumors Drugs Revenue and Market Share by Countries (2012-2017)
5.4 Europe Solid Tumors Drugs (Volume) by Application

6 GERMANY SOLID TUMORS DRUGS (VOLUME, VALUE AND SALES PRICE)

6.1 Germany Solid Tumors Drugs Sales and Value (2012-2017)
  6.1.1 Germany Solid Tumors Drugs Sales and Growth Rate (2012-2017)
  6.1.2 Germany Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
  6.1.3 Germany Solid Tumors Drugs Sales Price Trend (2012-2017)
6.2 Germany Solid Tumors Drugs Sales and Market Share by Manufacturers
6.3 Germany Solid Tumors Drugs Sales and Market Share by Type
6.4 Germany Solid Tumors Drugs Sales and Market Share by Application

7 FRANCE SOLID TUMORS DRUGS (VOLUME, VALUE AND SALES PRICE)

7.1 France Solid Tumors Drugs Sales and Value (2012-2017)
  7.1.1 France Solid Tumors Drugs Sales and Growth Rate (2012-2017)
  7.1.2 France Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
  7.1.3 France Solid Tumors Drugs Sales Price Trend (2012-2017)
7.2 France Solid Tumors Drugs Sales and Market Share by Manufacturers
7.3 France Solid Tumors Drugs Sales and Market Share by Type
7.4 France Solid Tumors Drugs Sales and Market Share by Application

8 UK SOLID TUMORS DRUGS (VOLUME, VALUE AND SALES PRICE)

8.1 UK Solid Tumors Drugs Sales and Value (2012-2017)
  8.1.1 UK Solid Tumors Drugs Sales and Growth Rate (2012-2017)
  8.1.2 UK Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
  8.1.3 UK Solid Tumors Drugs Sales Price Trend (2012-2017)
8.2 UK Solid Tumors Drugs Sales and Market Share by Manufacturers
8.3 UK Solid Tumors Drugs Sales and Market Share by Type
8.4 UK Solid Tumors Drugs Sales and Market Share by Application

9 RUSSIA SOLID TUMORS DRUGS (VOLUME, VALUE AND SALES PRICE)

9.1 Russia Solid Tumors Drugs Sales and Value (2012-2017)
  9.1.1 Russia Solid Tumors Drugs Sales and Growth Rate (2012-2017)
  9.1.2 Russia Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
  9.1.3 Russia Solid Tumors Drugs Sales Price Trend (2012-2017)
9.2 Russia Solid Tumors Drugs Sales and Market Share by Manufacturers
9.3 Russia Solid Tumors Drugs Sales and Market Share by Type
9.4 Russia Solid Tumors Drugs Sales and Market Share by Application

10 ITALY SOLID TUMORS DRUGS (VOLUME, VALUE AND SALES PRICE)

10.1 Italy Solid Tumors Drugs Sales and Value (2012-2017)
  10.1.1 Italy Solid Tumors Drugs Sales and Growth Rate (2012-2017)
  10.1.2 Italy Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
  10.1.3 Italy Solid Tumors Drugs Sales Price Trend (2012-2017)
10.2 Italy Solid Tumors Drugs Sales and Market Share by Manufacturers
10.3 Italy Solid Tumors Drugs Sales and Market Share by Type
10.4 Italy Solid Tumors Drugs Sales and Market Share by Application

11 SPAIN SOLID TUMORS DRUGS (VOLUME, VALUE AND SALES PRICE)

11.1 Spain Solid Tumors Drugs Sales and Value (2012-2017)
  11.1.1 Spain Solid Tumors Drugs Sales and Growth Rate (2012-2017)
  11.1.2 Spain Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
  11.1.3 Spain Solid Tumors Drugs Sales Price Trend (2012-2017)
11.2 Spain Solid Tumors Drugs Sales and Market Share by Manufacturers
11.3 Spain Solid Tumors Drugs Sales and Market Share by Type
11.4 Spain Solid Tumors Drugs Sales and Market Share by Application

12 BENELUX SOLID TUMORS DRUGS (VOLUME, VALUE AND SALES PRICE)

12.1 Benelux Solid Tumors Drugs Sales and Value (2012-2017)
  12.1.1 Benelux Solid Tumors Drugs Sales and Growth Rate (2012-2017)
  12.1.2 Benelux Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
  12.1.3 Benelux Solid Tumors Drugs Sales Price Trend (2012-2017)
12.2 Benelux Solid Tumors Drugs Sales and Market Share by Manufacturers
12.3 Benelux Solid Tumors Drugs Sales and Market Share by Type
12.4 Benelux Solid Tumors Drugs Sales and Market Share by Application

13 EUROPE SOLID TUMORS DRUGS MANUFACTURERS ANALYSIS

13.1 Hoffmann-La Roche
  13.1.1 Company Basic Information, Manufacturing Base and Competitors
  13.1.2 Product Type, Application and Specification
  13.1.3 Production, Revenue, Price and Gross Margin (2012-2017)
  13.1.4 Business Overview
13.2 Novartis
  13.2.1 Company Basic Information, Manufacturing Base and Competitors
  13.2.2 Product Type, Application and Specification
  13.2.3 Production, Revenue, Price and Gross Margin (2012-2017)
  13.2.4 Business Overview
13.3 Celgene
  13.3.1 Company Basic Information, Manufacturing Base and Competitors
  13.3.2 Product Type, Application and Specification
  13.3.3 Production, Revenue, Price and Gross Margin (2012-2017)
  13.3.4 Business Overview
13.4 Johnson & Johnson
  13.4.1 Company Basic Information, Manufacturing Base and Competitors
  13.4.2 Product Type, Application and Specification
  13.4.3 Production, Revenue, Price and Gross Margin (2012-2017)
  13.4.4 Business Overview
13.5 Pfizer
  13.5.1 Company Basic Information, Manufacturing Base and Competitors
  13.5.2 Product Type, Application and Specification
  13.5.3 Production, Revenue, Price and Gross Margin (2012-2017)
  13.5.4 Business Overview
13.6 BMS
  13.6.1 Company Basic Information, Manufacturing Base and Competitors
  13.6.2 Product Type, Application and Specification
  13.6.3 Production, Revenue, Price and Gross Margin (2012-2017)
  13.6.4 Business Overview
13.7 AbbVie
  13.7.1 Company Basic Information, Manufacturing Base and Competitors
  13.7.2 Product Type, Application and Specification
  13.7.3 Production, Revenue, Price and Gross Margin (2012-2017)
  13.7.4 Business Overview
13.8 AbGenomics
  13.8.1 Company Basic Information, Manufacturing Base and Competitors
  13.8.2 Product Type, Application and Specification
  13.8.3 Production, Revenue, Price and Gross Margin (2012-2017)
  13.8.4 Business Overview
13.9 ADC Therapeutics
  13.9.1 Company Basic Information, Manufacturing Base and Competitors
  13.9.2 Product Type, Application and Specification
  13.9.3 Production, Revenue, Price and Gross Margin (2012-2017)
  13.9.4 Business Overview

13 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

13.1 Marketing Channel
  13.1.1 Direct Marketing
  13.1.2 Indirect Marketing
  13.1.3 Marketing Channel Development Trend
13.2 Market Positioning
  13.2.1 Pricing Strategy
  13.2.2 Brand Strategy
  13.2.3 Target Client
13.3 Distributors/Traders List

14 MARKET EFFECT FACTORS ANALYSIS

14.1 Technology Progress/Risk
  14.1.1 Substitutes Threat
  14.1.2 Technology Progress in Related Industry
14.2 Consumer Needs/Customer Preference Change
14.3 Economic/Political Environmental Change

15 EUROPE SOLID TUMORS DRUGS MARKET FORECAST (2017-2022)

15.1 Germany Market Forecast (2017-2022)
15.2 France Market Forecast (2017-2022)
15.3 UK Market Forecast (2017-2022)
15.4 Russia Market Forecast (2017-2022)
15.5 Italy Market Forecast (2017-2022)
15.6 Spain Market Forecast (2017-2022)
15.7 Benelux Market Forecast (2017-2022)
15.8 Europe Solid Tumors Drugs Market Forecast by Type (2017-2022)
15.9 Europe Solid Tumors Drugs Market Forecast by Application (2017-2022)

16 APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Solid Tumors Drugs
Table Classification of Solid Tumors Drugs
Figure Europe Sales Market Share of Solid Tumors Drugs by Type in 2016
Table Application of Solid Tumors Drugs
Figure Europe Sales Market Share of Solid Tumors Drugs by Application in 2016
Figure Germany Solid Tumors Drugs Revenue and Growth Rate (2012-2022)
Figure France Solid Tumors Drugs Revenue and Growth Rate (2012-2022)
Figure UK Solid Tumors Drugs Revenue and Growth Rate (2012-2022)
Figure Russia Solid Tumors Drugs Revenue and Growth Rate (2012-2022)
Figure Italy Solid Tumors Drugs Revenue and Growth Rate (2012-2022)
Figure Spain Solid Tumors Drugs Revenue and Growth Rate (2012-2022)
Figure Benelux Solid Tumors Drugs Revenue and Growth Rate (2012-2022)
Figure Europe Solid Tumors Drugs Sales and Growth Rate (2012-2022)
Figure Europe Solid Tumors Drugs Revenue and Growth Rate (2012-2022)
Table Europe Solid Tumors Drugs Sales of Key Manufacturers (2015 and 2016)
Table Europe Solid Tumors Drugs Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Solid Tumors Drugs Sales Share by Manufacturers
Figure 2016 Solid Tumors Drugs Sales Share by Manufacturers
Table Europe Solid Tumors Drugs Revenue by Manufacturers (2015 and 2016)
Table Europe Solid Tumors Drugs Revenue Share by Manufacturers (2015 and 2016)
Table 2015 Europe Solid Tumors Drugs Revenue Share by Manufacturers
Table 2016 Europe Solid Tumors Drugs Revenue Share by Manufacturers
Table Europe Solid Tumors Drugs Sales and Market Share by Type (2012-2017)
Table Europe Solid Tumors Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Solid Tumors Drugs by Type (2012-2017)
Figure Europe Solid Tumors Drugs Sales Growth Rate by Type (2012-2017)
Table Europe Solid Tumors Drugs Revenue and Market Share by Type (2012-2017)
Table Europe Solid Tumors Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Solid Tumors Drugs by Type (2012-2017)
Figure Europe Solid Tumors Drugs Revenue Growth Rate by Type (2012-2017)
Table Europe Solid Tumors Drugs Sales and Market Share by Countries (2012-2017)
Table Europe Solid Tumors Drugs Sales Share by Countries (2012-2017)
Figure Sales Market Share of Solid Tumors Drugs by Countries (2012-2017)
Table Europe Solid Tumors Drugs Revenue and Market Share by Countries (2012-2017)
Table Europe Solid Tumors Drugs Revenue Share by Countries (2012-2017)
Figure Revenue Market Share of Solid Tumors Drugs by Countries (2012-2017)
Table Europe Solid Tumors Drugs Sales and Market Share by Application (2012-2017)
Table Europe Solid Tumors Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Solid Tumors Drugs by Application (2012-2017)
Figure Germany Solid Tumors Drugs Sales and Growth Rate (2012-2017)
Figure Germany Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
Figure Germany Solid Tumors Drugs Sales Price Trend (2012-2017)
Table Germany Solid Tumors Drugs Sales by Manufacturers (2015 and 2016)
Table Germany Solid Tumors Drugs Market Share by Manufacturers (2015 and 2016)
Table Germany Solid Tumors Drugs Sales by Type (2015 and 2016)
Table Germany Solid Tumors Drugs Market Share by Type (2015 and 2016)
Table Germany Solid Tumors Drugs Sales by Application (2015 and 2016)
Table Germany Solid Tumors Drugs Market Share by Application (2015 and 2016)
Figure France Solid Tumors Drugs Sales and Growth Rate (2012-2017)
Figure France Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
Figure France Solid Tumors Drugs Sales Price Trend (2012-2017)
Table France Solid Tumors Drugs Sales by Manufacturers (2015 and 2016)
Table France Solid Tumors Drugs Market Share by Manufacturers (2015 and 2016)
Table France Solid Tumors Drugs Sales by Type (2015 and 2016)
Table France Solid Tumors Drugs Market Share by Type (2015 and 2016)
Table France Solid Tumors Drugs Sales by Application (2015 and 2016)
Table France Solid Tumors Drugs Market Share by Application (2015 and 2016)
Figure UK Solid Tumors Drugs Sales and Growth Rate (2012-2017)
Figure UK Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
Figure UK Solid Tumors Drugs Sales Price Trend (2012-2017)
Table UK Solid Tumors Drugs Sales by Manufacturers (2015 and 2016)
Table UK Solid Tumors Drugs Market Share by Manufacturers (2015 and 2016)
Table UK Solid Tumors Drugs Sales by Type (2015 and 2016)
Table UK Solid Tumors Drugs Market Share by Type (2015 and 2016)
Table UK Solid Tumors Drugs Sales by Application (2015 and 2016)
Table UK Solid Tumors Drugs Market Share by Application (2015 and 2016)
Figure Russia Solid Tumors Drugs Sales and Growth Rate (2012-2017)
Figure Russia Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
Figure Russia Solid Tumors Drugs Sales Price Trend (2012-2017)
Table Russia Solid Tumors Drugs Sales by Manufacturers (2015 and 2016)
Table Russia Solid Tumors Drugs Market Share by Manufacturers (2015 and 2016)
Table Russia Solid Tumors Drugs Sales by Type (2015 and 2016)
Table Russia Solid Tumors Drugs Market Share by Type (2015 and 2016)
Table Russia Solid Tumors Drugs Sales by Application (2015 and 2016)
Table Russia Solid Tumors Drugs Market Share by Application (2015 and 2016)
Figure Italy Solid Tumors Drugs Sales and Growth Rate (2012-2017)
Figure Italy Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
Figure Italy Solid Tumors Drugs Sales Price Trend (2012-2017)
Table Italy Solid Tumors Drugs Sales by Manufacturers (2015 and 2016)
Table Italy Solid Tumors Drugs Market Share by Manufacturers (2015 and 2016)
Table Italy Solid Tumors Drugs Sales by Type (2015 and 2016)
Table Italy Solid Tumors Drugs Market Share by Type (2015 and 2016)
Table Italy Solid Tumors Drugs Sales by Application (2015 and 2016)
Table Italy Solid Tumors Drugs Market Share by Application (2015 and 2016)
Figure Spain Solid Tumors Drugs Sales and Growth Rate (2012-2017)
Figure Spain Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
Figure Spain Solid Tumors Drugs Sales Price Trend (2012-2017)
Table Spain Solid Tumors Drugs Sales by Manufacturers (2015 and 2016)
Table Spain Solid Tumors Drugs Market Share by Manufacturers (2015 and 2016)
Table Spain Solid Tumors Drugs Sales by Type (2015 and 2016)
Table Spain Solid Tumors Drugs Market Share by Type (2015 and 2016)
Table Spain Solid Tumors Drugs Sales by Application (2015 and 2016)
Table Spain Solid Tumors Drugs Market Share by Application (2015 and 2016)
Figure Benelux Solid Tumors Drugs Sales and Growth Rate (2012-2017)
Figure Benelux Solid Tumors Drugs Revenue and Growth Rate (2012-2017)
Figure Benelux Solid Tumors Drugs Sales Price Trend (2012-2017)
Table Benelux Solid Tumors Drugs Sales by Manufacturers (2015 and 2016)
Table Benelux Solid Tumors Drugs Market Share by Manufacturers (2015 and 2016)
Table Benelux Solid Tumors Drugs Sales by Type (2015 and 2016)
Table Benelux Solid Tumors Drugs Market Share by Type (2015 and 2016)
Table Benelux Solid Tumors Drugs Sales by Application (2015 and 2016)
Table Benelux Solid Tumors Drugs Market Share by Application (2015 and 2016)
Table Hoffmann-La Roche Basic Information List
Table Hoffmann-La Roche Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Hoffmann-La Roche Solid Tumors Drugs Sales Market Share (2012-2017)
Table Novartis Basic Information List
Table Novartis Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Novartis Solid Tumors Drugs Sales Market Share (2012-2017)
Table Celgene Basic Information List
Table Celgene Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Celgene Solid Tumors Drugs Sales Market Share (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table Johnson & Johnson Solid Tumors Drugs Sales Market Share (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Pfizer Solid Tumors Drugs Sales Market Share (2012-2017)
Table BMS Basic Information List
Table BMS Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table BMS Solid Tumors Drugs Sales Market Share (2012-2017)
Table AbbVie Basic Information List
Table AbbVie Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Figure AbbVie Solid Tumors Drugs Sales Market Share (2012-2017)
Table AbGenomics Basic Information List
Table AbGenomics Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Table AbGenomics Solid Tumors Drugs Sales Market Share (2012-2017)
Table ADC Therapeutics Basic Information List
Table ADC Therapeutics Solid Tumors Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
Figure ADC Therapeutics Solid Tumors Drugs Sales Market Share (2012-2017).
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Solid Tumors Drugs
Figure Manufacturing Process Analysis of Solid Tumors Drugs
Figure Solid Tumors Drugs Industrial Chain Analysis
Table Raw Materials Sources of Solid Tumors Drugs Major Manufacturers in 2016
Table Major Buyers of Solid Tumors Drugs
Table Distributors/Traders List
Figure Germany Solid Tumors Drugs Sales and Growth Rate Forecast (2017-2022)
Figure Germany Solid Tumors Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure France Solid Tumors Drugs Sales and Growth Rate Forecast (2017-2022)
Figure France Solid Tumors Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure UK Solid Tumors Drugs Sales and Growth Rate Forecast (2017-2022)
Figure UK Solid Tumors Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure Russia Solid Tumors Drugs Sales and Growth Rate Forecast (2017-2022)
Figure Russia Solid Tumors Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure Italy Solid Tumors Drugs Sales and Growth Rate Forecast (2017-2022)
Figure Italy Solid Tumors Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure Spain Solid Tumors Drugs Sales and Growth Rate Forecast (2017-2022)
Figure Spain Solid Tumors Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure Benelux Solid Tumors Drugs Sales and Growth Rate Forecast (2017-2022)
Figure Benelux Solid Tumors Drugs Revenue and Growth Rate Forecast (2017-2022)
Table Europe Solid Tumors Drugs Sales Forecast by Type (2017-2022)
Table Europe Solid Tumors Drugs Sales Forecast by Application (2017-2022)

COMPANIES MENTIONED

Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
AbbVie
AbGenomics
ADC Therapeutics
TG Therapeutics
Polaris Pharmaceuticals
Immunogen
CTI BioPharma
Chugai Pharmaceutical
NewLink Genetics